Department of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
J Diabetes. 2024 Nov;16(11):e70024. doi: 10.1111/1753-0407.70024.
Recent advances highlight the role of gut virome, particularly phageome, in metabolic disorders such as obesity, type 2 diabetes mellitus, metabolic dysfunction-associated fatty liver disease, and cardiovascular diseases, including hypertension, stroke, coronary heart disease, and hyperlipidemia. While alterations in gut bacteria are well-documented, emerging evidence suggests that changes in gut viruses also contribute to these disorders. Bacteriophages, the most abundant gut viruses, influence bacterial populations through their lytic and lysogenic cycles, potentially modulating the gut ecosystem and metabolic pathways. Phage therapy, previously overshadowed by antibiotics, is experiencing renewed interest due to rising antibiotic resistance. It offers a novel approach to precisely edit the gut microbiota, with promising applications in metabolic diseases. In this review, we summarize recent discoveries about gut virome in metabolic disease patients, review preclinical and clinical studies of phage therapy on metabolic diseases as well as the breakthroughs and currently faced problems and concerns.
最近的研究进展强调了肠道病毒组，特别是噬菌体组，在代谢紊乱中的作用，如肥胖、2 型糖尿病、代谢功能障碍相关脂肪性肝病以及心血管疾病，包括高血压、中风、冠心病和高脂血症。虽然肠道细菌的改变已有充分的记录，但新出现的证据表明，肠道病毒的变化也与这些疾病有关。噬菌体是最丰富的肠道病毒，通过其裂解和溶源周期影响细菌种群，可能调节肠道生态系统和代谢途径。噬菌体治疗曾因抗生素的出现而黯然失色，但由于抗生素耐药性的上升，现在又重新受到关注。它为精确编辑肠道微生物群提供了一种新方法，在代谢性疾病中有广泛的应用前景。在这篇综述中，我们总结了代谢疾病患者肠道病毒组的最新发现，回顾了噬菌体治疗代谢疾病的临床前和临床研究，以及突破和当前面临的问题和担忧。
